(AIM: SAR)

14 December 2017

Sareum Holdings plc

("Sareum" or "the Company")

Results of AGM

Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed.

-Ends-

For further information, please contact: 

Sareum Holdings plc

 

Tim Mitchell

01223 497 700

WH Ireland Limited (Nominated Adviser and Co-Broker)

 

Chris Fielding / James Sinclair-Ford

020 7220 1666

Hybridan LLP (Co-Broker)

 

Claire Noyce

020 3764 2341

Citigate Dewe Rogerson (Media enquiries)

 

Shabnam Bashir/ Mark Swallow/ David Dible

020 7282 9571


Notes for editors: 

Sareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and generating value through licensing them to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Its most advanced programme, SRA737, is a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology and in clinical trials targeting a range of advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.

Sareum is also advancing programmes to develop novel tyrosine kinase 2 (TYK2) inhibitors in autoimmune diseases and cancers, and Aurora+FLT3 inhibitors in haematological cancers, which are in the IND-enabling preclinical and lead optimisation stages.

The Company’s drug discovery technology platform (SKIL® - Sareum Kinase Inhibitor Library) is being applied to generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk

- Ends -

 

  • @Sareumplc Latest tweet

    Eli Lilly's Chk1 inhibitor, prexasertib, shows clinical activity in ovarian cancer. Update from Sierra Oncology on… https://t.co/CrnUdzIr5x via @Sareumplc
    View more